Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060904 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01060904 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 51 participants.
The verdict
NCT01060904, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with multi-agent chemotherapy in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, two-arm, open-label dose escalation study designed to define the maximum tolerated dose, pharmacokinetics, immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline therapy.
Interventions
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG vinblastine
- DRUG dacarbazine
- DRUG bleomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01060904
The ClinicalTrials.gov registry entry for NCT01060904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which doxorubicin is the first listed.
NCT01060904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01060904 about?
NCT01060904 is a clinical study titled "A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma". The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with multi-agent chemotherapy in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, two-arm, open-label dose escalation study designed to define the maximum tolerated dose, pharmacokin...
What is the current status of trial NCT01060904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2010-01. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01060904?
The interventions under investigation include: doxorubicin (DRUG), brentuximab vedotin (DRUG), vinblastine (DRUG), dacarbazine (DRUG), bleomycin (DRUG).
Who is sponsoring clinical trial NCT01060904?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.